Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZKLJ02 in Healthy Chinese Participants
NCT07638098Phase 1Completed
- Sponsor
- Yunnan Zhongke Longjin Biotechnology
- Start
- Aug 2025
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZKLJ02 (5 arms), sponsored by Yunnan Zhongke Longjin Biotechnology. Primary endpoint: Adverse Events at 24 hours. Started Aug 2025; status: completed.
02
Drugs
ZKLJ02
Beyond the preview
Go deeper on NCT07638098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638098.